Allergy Therapeutics trading ahead of expectations

0
50
  • Allergy Therapeutics hails positive results from field trial of its short-course grass pollen immunotherapy
  • Allergy Therapeutics’ peanut vaccine study further de-risks programme says broker
  • Allergy Therapeutics’ set for phase III trial after positive results from grass pollen immunotherapy
Allergy Therapeutics PLC -

Quick facts: Allergy Therapeutics PLC

Follow

View company profile

Allergy Therapeutics specialises in the research and development of treatments and vaccines for allergies such as hay fever.

The company is well-established in Europe with a pipeline of products also in clinical development for grass, tree and house dust mites and a peanut allergy vaccine in pre-clinical stages.

25 Oct 2021

() has hailed the results from a study that it said demonstrated a “clear treatment effect” from its short-course immunotherapy targeting grass pollen allergies.

The exploratory field trial was designed to evaluate the efficacy and safety of Grass MATA MPL.

The primary aim was achieved with the jab providing a “clinically relevant improvement” across both active treatment groups compared to placebo with no medicinal value.

Specifically, there was a 29.1% improvement in the symptoms for those on the six-week course, which rose to 36.8% for those receiving treatment over 14 weeks. Quality of life was also enhanced, the data showed. The drug was well tolerated.

Read more

23 Sep 2021

Allergy Therapeutics PLC (AIM:AGY, FRA:HHU) said it has enough cash to fund the current clinical trials of its grass allergy and peanut allergy vaccines with just a small amount of debt.

The next milestones for investors to look forward to include results from the Grass MATA MPL G309 exploratory field trial in the autumn, the pre-application meeting with the US Food and Drug Administration (FDA) for VLP Peanut, followed by the start in 2022 of the VLP Peanut Phase I PROTECT study in the US.

Read more

16 Sep 2021

Allergy Therapeutics PLC (AIM:AGY, FRA:HHU) said ImmunoBON, its protein-based oral product for the treatment of allergies, was voted Most Innovative Product 2021 at the Pharma Trends Image and Innovation Awards in Germany.

The awards, held every year, are based on the Pharma Trend benchmark study, which seeks the views of 700 physicians, 100 pharmacists and 600 patients in Germany.

Read more

03 Aug 2021

Allergy Therapeutics PLC (AIM:AGY, FRA:HHU)’s study evaluating biomarkers from peanut-allergic patients’ blood samples using its VLP Peanut vaccine candidate confirm its hypoallergic potential and should strengthen the company’s Phase I study IND application to the FDA in late 2021, says finnCap.

While the broker’s target price remains 45p, it adds there is substantial potential upside as VLP Peanut progresses through the clinic.

Read more

25 Oct 2021

() () Head of Business Innovation Alan Bullimore caught up with Proactive London to talk about the results from a study targeting grass pollen allergies.

The exploratory field trial was designed to evaluate the efficacy and safety of Grass MATA MPL.

As he explains there was a 29.1% improvement in the symptoms for those on the six-week course, which rose to 36.8% for those receiving treatment over 14 weeks.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is…

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash…

FOR OUR FULL DISCLAIMER CLICK HERE

Allergy Therapeutics’ set for phase III trial after positive results from…

Allergy Therapeutics PLC (AIM:AGY) (LON:AGY) Head of Business Innovation Alan Bullimore caught up with Proactive London to talk about the results from a study targeting grass pollen allergies.

The exploratory field trial was designed to evaluate the efficacy and safety of Grass MATA…

11 hours, 41 minutes ago

3 min read

LEAVE A REPLY

Please enter your comment!
Please enter your name here